CRC Research Update — September 05, 2026
Today's colorectal cancer research highlights
kras
A collection of 66 issues
KRAS Mutation Enriches Gut Bacteria Linked to Tumor Growth
Skip to content
The CRC Digest
◇ RESEARCH
KRAS Mutation Enriches Gut Bacteria Linked to Tumor Growth
A study in KRAS-mutant CRC patients and mice found that KRAS reshapes the microbial community, enriching Bacteroides acidifaciens, which predicts poor prognosis and promotes malignant phenotypes in KRAS-mutant tumors. (Cell Host & Microbe)
This
Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC
Skip to content
The CRC Digest
◇ RESEARCH
Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC
Analysis of 6,762 samples across four age groups found that early-onset colorectal cancer (diagnosed before age 50) shows different mutation patterns compared to later-onset disease, with implications for testing guidelines and therapeutic development.
CRC Research Update — September 04, 2026
Today's colorectal cancer research highlights
Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRC
Skip to content
The CRC Digest
◇ RESEARCH
Nanoparticle Platform Targets Radioresistance in KRAS-Mutant CRC
Researchers developed sulfasalazine-loaded hafnium oxide nanoparticles (HfO2@SAS) to overcome radiotherapy resistance in KRAS-mutant colorectal cancer by targeting the SLC7A11/GPX4 pathway and inducing ferroptosis (a form of cell death). (Biomaterials)
This content is informational only
CRC Research Update — September 03, 2026
Today's colorectal cancer research highlights
HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer
Skip to content
The CRC Digest
HER2-Targeted Zanidatamab Produces Response in KRAS-Mutated Rectal Cancer
A case report describes a significant response in a 54-year-old male with HER2-amplified, KRAS G12D-mutated metastatic rectal cancer treated with a zanidatamab-based combination regimen. (Frontiers in Immunology)
This content is informational only and does not constitute
CRC Research Update — September 02, 2026
Today's colorectal cancer research highlights
Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer
Skip to content
The CRC Digest
◇ RESEARCH
Direct inhibitors for KRAS G12D and G12V mutations now in development for colorectal cancer
While approved KRAS therapies target only the rare G12C mutation, new drugs including MRTX1133, zoldonrasib, and daraxonrasib are being developed to directly target G12D and G12V—the most common
CRISPR-Cas9 electroporation targets KRAS G12V mutation in CRC cells
Skip to content
The CRC Digest
◇ RESEARCH
CRISPR-Cas9 electroporation targets KRAS G12V mutation in CRC cells
Researchers used direct electroporation of Cas9 ribonucleoproteins to achieve allele-specific disruption of KRAS p.G12V in SW480 colorectal cancer cells, assessing delivery efficiency and on-target editing. (Iranian Journal of Basic Medical Sciences)
This content